Atherosclerosis Pathophysiology

Definition

Atherosclerosis is a chronic inflammatory disease of large and medium-sized arteries characterized by the accumulation of lipids, immune cells, and fibrous material within the arterial wall (intima). It is the primary cause of ASCVD and responsible for the majority of MI, ischaemic stroke, and PAD events. Pathogenesis involves endothelial damage, LDL-C oxidation, macrophage foam cell formation, and a self-sustaining inflammatory cycle that drives plaque progression, instability, and rupture.

Key Concepts

Plaque Initiation — Endothelial Damage and LDL Deposition

• Endothelial damage is triggered by multiple modulators: excess LDL-C, cigarette smoke toxins, hypertension, and oxidative stress; this is the initiating step
• Damaged endothelium allows deposition of circulating LDL-C in the tunica intima beneath endothelial cells, where it undergoes spontaneous oxidation → oxidized LDL (Ox-LDL) sources/pcsk9-jaha-2022 (medium)
• Ox-LDL acquires damage-associated molecular patterns recognized by pattern recognition receptors: CD36, TLR4, LOX-1, and CRP — triggering proinflammatory cytokine production and phagocytic internalization sources/pcsk9-jaha-2022 (medium)

Oxidation Cascade — LDL Oxidation

• Minimally oxidized LDL: low affinity for macrophage scavenger receptors (does not directly trigger foam cell formation); stimulates adhesion molecules, chemokines, and cytokines → extravasation of immune cells into arterial wall; also induces tissue factor expression in endothelial cells sources/pcsk9-jaha-2022 (medium)
• Extensively oxidized LDL: stimulates VSMC proliferation; recognized by macrophage scavenger receptors → engulfment and foam cell formation → fatty plaque accumulation sources/pcsk9-jaha-2022 (medium)
• Enzymatic LDL oxidation: lipoxygenase (intracellular enzyme in macrophages — both direct enzymatic and indirect radical-mediated LDL oxidation); myeloperoxidase (expressed in activated neutrophils, monocytes, and resident macrophages — uses H2O2 + Cl⁻ → hypochlorous acid + radical oxidants) sources/pcsk9-jaha-2022 (medium)
• HDL oxidation: myeloperoxidase-derived oxidants (+ peroxyl/hydroxyl radicals) oxidize HDL → malondialdehyde and 4-hydroxynonenal modify amino acid side chains → impaired HDL antiatherogenic function; acrolein aldehydes inhibit HDL cholesterol transport; HDL oxidation reduces reverse cholesterol transport capacity, amplifying atherogenesis sources/pcsk9-jaha-2022 (medium)
• Low-dose reactive species (e.g., Nox4-generated H2O2) can paradoxically mediate vasoprotective effects — oxidation in atherogenesis is not unidirectionally harmful

Foam Cell Formation and Plaque Progression

• Ox-LDL-mediated proinflammatory response recruits circulating monocytes into the intima → differentiation into resident macrophages
• Macrophages engulf Ox-LDL via scavenger receptors (CD36, SR-A) → phenotypic transformation into foam cells → lipid-laden cell death → proinflammatory cytokine release → fatty lesion formation
• This chronic cycle of cytokine release (IL-1β, IL-6, TNF-α, MCP-1) drives further monocyte infiltration, more foam cell development, plaque deposition, and eventually arterial narrowing or occlusion sources/pcsk9-jaha-2022 (medium)
• VSMCs also contribute: when fatty deposits accumulate, VSMCs migrate from the media and phenotypically transform into macrophage-like cells → engulf oxidized species → become foam cells → apoptosis and plaque deposition
• Plaque instability and rupture → thrombus formation → MI and thrombolytic stroke

PCSK9's Role in Atherosclerotic Inflammation

• Beyond cholesterol regulation, PCSK9 is expressed in VSMCs and macrophages within the arterial plaque (not only hepatocytes)
• Circulating PCSK9 enters the intimal space where it stimulates macrophages to produce proinflammatory cytokines → VSMC migration and transformation → foam cell formation (in vitro and murine data) sources/pcsk9-jaha-2022 (medium)
• PCSK9 expression is upregulated by inflammatory stimulants (LPS, zymosan, turpentine) in hepatic tissue → bidirectional link: inflammation ↑ PCSK9 → ↑ LDL-C + ↑ direct inflammatory signalling → more atherosclerosis
• PCSK9 positively correlates with CRP, white blood cell count, and plaque necrotic core content in clinical studies (some independent of LDL-C) sources/pcsk9-jaha-2022 (medium)
• PCSK9 siRNA/shRNA in murine models: silencing PCSK9 → decreased atherosclerotic plaque area, macrophage content, TLR4 expression, and NF-κB activation in ApoE-/- mice (Tang et al)
• Critical caveat: evolocumab did NOT reduce CRP in FOURIER — clinical trials have not confirmed LDL-R-independent anti-inflammatory PCSK9 inhibitor effects; preclinical-clinical discordance remains unresolved sources/pcsk9-jaha-2022 (medium) — see Contradictions

TLR4/NF-κB — The Candidate Signalling Pathway

• TLR4 is a transmembrane pattern recognition receptor on innate immune cells (macrophages, endothelial cells); normally responds to LPS via gram-negative bacteria; triggers MyD88 → IκB phosphorylation/degradation → NF-κB nuclear translocation → proinflammatory cytokines (IL-1, IL-6, IL-12, TNF-α, MCP-1)
• In atherosclerosis, endogenous ligands (primarily Ox-LDL) drive TLR4 activation — TLR4 deletion in ApoE-/- mice markedly reduces plaque formation without any pathogen exposure sources/pcsk9-jaha-2022 (medium)
• PCSK9 overexpression → TLR4 upregulation → NF-κB activation; PCSK9 silencing → reversal; suggests PCSK9 is upstream of TLR4 in this pathway
• CD36 amplifies TLR4/NF-κB signalling in macrophages in response to Ox-LDL — potential synergistic pathway

PCSK9–Resistin Structural Homology and the CRD Hypothesis

• PCSK9 has a unique C-terminal cysteine-rich domain (CRD) with a 3-jelly-roll structure found in only ONE other protein: resistin
• Resistin (FIZZ family protein): expressed in atherosclerotic macrophages; CRD domain binds and activates both TLR4 and CAP1 → NF-κB nuclear translocation → proinflammatory cytokines; promotes LDL-R degradation; stimulates foam cell formation via CD36 upregulation sources/pcsk9-jaha-2022 (medium)
• PCSK9–CAP1 binding confirmed: PCSK9 binds CAP1 via the SH3 binding domain on its CRD in human liver/kidney cells → mediates LDL-R endocytosis and lysosomal degradation (same domain as resistin-CAP1 binding)
• Unconfirmed hypothesis: PCSK9's CRD may also bind TLR4 directly (as resistin does), triggering NF-κB in immune cells — this would explain LDL-R-independent inflammatory effects but has NOT been experimentally demonstrated in atherosclerotic plaque cells sources/pcsk9-jaha-2022 (medium)

Contradictions / Open Questions

• FOURIER/clinical trial data vs preclinical evidence: Evolocumab (FOURIER) had no effect on CRP levels by high-sensitivity assay in the clinical trial; no RCT has demonstrated PCSK9 inhibitor-mediated reduction of inflammatory biomarkers independent of LDL-C lowering — fundamentally challenges the clinical relevance of the LDL-R-independent inflammatory mechanism proposed in this review sources/pcsk9-jaha-2022 (medium); sources/pcsk9-inhibitors-nrc-2018 (very high)
• Conflicting data on PCSK9 and carotid intima-media thickness: one study showed positive correlation between plasma PCSK9 and carotid atherosclerosis progression; another showed no correlation between PCSK9 concentration and carotid IMT sources/pcsk9-jaha-2022 (medium)
• Conflicting plaque imaging data: one study found PCSK9 correlates with plaque necrotic core independent of LDL-C; another showed evolocumab did not affect plaque composition — raises uncertainty about the clinical impact of PCSK9 inhibition on plaque biology beyond LDL-C reduction
• PROSPER genetic variant data: PCSK9 genetic variations that decreased LDL-C did NOT decrease CHD risk in the PROSPER cohort — this contradicts the expected LDL-C-mediated benefit and suggests the relationship between PCSK9 genotype and cardiovascular risk may be more complex in elderly patients
• PCSK9-TLR4 direct binding: the core structural hypothesis has never been tested in atherosclerotic plaque cells; all evidence for PCSK9-TLR4 interaction is indirect (upregulation correlation, not direct binding assay); direct confirmation would substantially strengthen the hypothesis

Connections

• Related to concepts/PCSK9-Inhibitors — PCSK9's role in plaque biology; LDL-R-independent inflammation hypothesis; structural mechanism via CRD
• Related to concepts/Dyslipidemia-Management — LDL-C as primary driver of atherosclerosis initiation; statin and PCSK9i as primary management
• Related to concepts/Clonal-Hematopoiesis — CH/CHIP as another inflammatory pathway to ASCVD (TET2→IL-1β/NLRP3)
• Related to concepts/Lipoprotein-a — Lp(a) OxPL as another proatherogenic, pro-inflammatory lipid species
• Related to concepts/GWAS-Cardiac-Genetics — Mendelian randomization validates LDL-C as causal ASCVD factor; deprioritises HDL-C and CRP as drug targets despite inflammatory mechanisms

Sources

• sources/pcsk9-jaha-2022 (medium)